You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 21, November 25, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (36)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Infectious Diseases, Other
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Risk Factors for Fluoroquinolone Resistance in Nosocomial Escherichia coli and Klebsiella pneumoniae Infections

Ebbing Lautenbach, MD,MPH; Neil O. Fishman, MD; Warren B. Bilker, PhD; Analia Castiglioni, MD; Joshua P. Metlay, MD,PhD; Paul H. Edelstein, MD; Brian L. Strom, MD,MPH

Arch Intern Med. 2002;162:2469-2477.

Background  The incidence of fluoroquinolone (FQ) resistance has increased markedly in recent years. Even in the common nosocomial pathogens Escherichia coli and Klebsiella pneumoniae, in which the emergence of FQ resistance was believed to be unlikely, increasing resistance to these agents has been noted. Risk factors for FQ resistance in these pathogens remain unknown. Although FQs are important components of the present antimicrobial arsenal, their continued usefulness is threatened by rising FQ resistance.

Objective  To identify risk factors for nosocomial FQ resistance.

Methods  A case-control study of hospitalized patients with infections due to FQ-resistant and FQ-susceptible E coli and K pneumoniae occurring between January 1, 1998, and June 30, 1999.

Results  We included 123 patients with nosocomial FQ-resistant infections and 70 randomly selected patients with nosocomial FQ-susceptible infections. Independent risk factors (adjusted odds ratio [95% confidence interval]) for FQ resistance were (1) recent FQ use (5.25 [1.81-15.26]); (2) residence in a long-term care facility (3.65 [1.64-8.15]); (3) recent aminoglycoside use (8.86 [1.71-45.99]); and (4) older age (1.03 [1.01-1.06]).

Conclusions  Recent FQ use, residence in a long-term care facility, recent aminoglycoside use, and older age were all noted to be independent risk factors for FQ resistance among patients with nosocomial E coli and K pneumoniae infections. Efforts should be directed at recognition and modification of these risk factors to curb the rise in FQ resistance and preserve the utility of these agents in the treatment of common nosocomial gram-negative infections.


From the Divisions of Infectious Diseases (Drs Lautenbach and Fishman) and General Internal Medicine (Drs Castiglioni, Metlay, and Strom) of the Department of Medicine, the Department of Biostatistics and Epidemiology (Drs Lautenbach, Bilker, Metlay, and Strom), the Department of Pathology and Laboratory Medicine (Dr Edelstein), the Center for Clinical Epidemiology and Biostatistics (Drs Lautenbach, Bilker, Metlay, and Strom), and the University of Pennsylvania Centers for Research and Education on Therapeutics (Drs Lautenbach, Metlay, and Strom), University of Pennsylvania School of Medicine, Philadelphia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pyogenic liver abscess in the elderly: clinical features, outcomes and prognostic factors
Chen et al.
Age Ageing 2009;38:271-276.
ABSTRACT | FULL TEXT  

Antimicrobial resistance in hospitals: How concerned should we be?
Mulvey and Simor
CMAJ 2009;180:408-415.
FULL TEXT  

Impact of Empiric Antibiotic Therapy on Outcomes in Patients with Pseudomonas aeruginosa Bacteremia
Osih et al.
Antimicrob. Agents Chemother. 2007;51:839-844.
ABSTRACT | FULL TEXT  

Impact of Inadequate Initial Antimicrobial Therapy on Mortality in Infections Due to Extended-Spectrum {beta}-Lactamase-Producing Enterobacteriaceae: Variability by Site of Infection
Hyle et al.
Arch Intern Med 2005;165:1375-1380.
ABSTRACT | FULL TEXT  

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes
Hsu et al.
J Antimicrob Chemother 2005;55:535-541.
ABSTRACT | FULL TEXT  

Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002
Kern et al.
J Antimicrob Chemother 2005;55:57-60.
ABSTRACT | FULL TEXT  

Colonization with Extraintestinal Pathogenic Escherichia coli among Nursing Home Residents and Its Relationship to Fluoroquinolone Resistance
Maslow et al.
Antimicrob. Agents Chemother. 2004;48:3618-3620.
ABSTRACT | FULL TEXT  

Risk Factors for Community-Acquired Ciprofloxacin-Resistant Escherichia coli Urinary Tract Infection
Killgore et al.
The Annals of Pharmacotherapy 2004;38:1148-1152.
ABSTRACT | FULL TEXT  

The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant Escherichia coli and Klebsiella pneumoniae May Be Lower than Previously Reported
Bolon et al.
Antimicrob. Agents Chemother. 2004;48:1934-1940.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.